Ben Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.
Ben Jones, Senior Director of Government Relations, McKesson Specialty Health, The US Oncology Network, discusses how the affordable care act will affect oncologists.
Jones speculates that the act will provide both uncertainty and opportunity for community oncologists. In addition to providing coverage for clinical trials for patients that are already insured, the act will potentially cover an additional 30 million individuals that are currently uninsured through state-based exchanges or expanded Medicaid.
Jones hopes the act will allow for early cancer detection and provide patients with care before the disease becomes too aggressive.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More